NDAORALCAPSULE
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
Korea Post Marketing Surveillance (PMS) Study of Talzenna®
Started Jun 2027
600 enrolled
Breast Neoplasms
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Started Oct 2025
126 enrolled
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
Started Jul 2025
1 enrolled
Prostate Cancer
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
Started Apr 2025
3 enrolled
Breast Cancer
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Started Apr 2023
33 enrolled
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Loss of Exclusivity
LOE Date
Oct 20, 2031
68 months away
Patent Expiry
Oct 20, 2031
Exclusivity Expiry
Jun 20, 2026